Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
47 (est)
Dicerna Pharmaceuticals was founded in 2007 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Dicerna Pharmaceuticals

Douglas Fambrough

Douglas Fambrough

President and Chief Executive Officer
Bob D. Brown Ph.D

Bob D. Brown Ph.D

Chief Scientific Officer, Senior Vice President
Jack Green

Jack Green

Chief Financial Officer
Jennifer Lockridge Ph.D

Jennifer Lockridge Ph.D

Vice President, Program Development
David Miller Ph.D

David Miller Ph.D

Senior Vice President, Corporate Operations
Ralf Rosskamp M.D

Ralf Rosskamp M.D

Chief Medical Officer
Show more

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridge Park Dr
Show all (1)
Report incorrect company information

Dicerna Pharmaceuticals Financials and Metrics

Dicerna Pharmaceuticals Financials

Dicerna Pharmaceuticals's revenue was reported to be $1.18 m in FY, 2017
USD

Revenue (FY, 2017)

1.2 m

Net income (FY, 2017)

(60 m)

EBIT (FY, 2017)

(60.6 m)

Market capitalization (21-May-2018)

735.8 m

Closing share price (21-May-2018)

13.9

Cash (31-Dec-2017)

68.8 m
Dicerna Pharmaceuticals's current market capitalization is $735.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

184 k295 k1.2 m

Revenue growth, %

60%

General and administrative expense

15.6 m19.2 m18.3 m25.9 m

R&D expense

29.5 m44 m41.7 m37 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

184 k184 k184 k162 k133 k252 k474 k

General and administrative expense

2.8 m4.4 m3.7 m5.4 m4.5 m4.9 m4.5 m4.7 m4.3 m5.5 m6.3 m6.7 m

R&D expense

5.3 m6.8 m7.5 m8.7 m11.9 m12.1 m11.3 m11 m10.1 m8.9 m9.3 m9 m

Operating expense total

8.1 m11.2 m11.2 m14.1 m16.4 m17 m15.7 m15.7 m14.4 m14.4 m15.6 m15.7 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1 m56.1 m20.9 m68.8 m

Accounts Receivable

254.7 m805.4 k

Inventories

1.2 m1.5 m2 m

Current Assets

97.3 m96.1 m47.8 m118.6 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

133.8 m77.7 m31.8 m22.6 m25.9 m52.9 m27.6 m29.2 m32.5 m22.9 m38.8 m31 m

Current Assets

134.7 m101.3 m93.7 m89.1 m96.7 m95.7 m81.8 m70.7 m59.4 m36.2 m91.7 m79.8 m

PP&E

911 k1.5 m1.9 m2.3 m2.6 m2.7 m2.5 m2.5 m2.4 m2 m1.8 m1.7 m

Total Assets

135.9 m124.2 m116 m92.7 m127.7 m113.6 m85.5 m74.3 m62.9 m39.4 m94.7 m82.7 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(47.9 m)(62.8 m)(59.5 m)(60 m)

Depreciation and Amortization

848 k727 k840 k778 k

Inventories

(44.3 m)

Accounts Payable

(97 k)1.4 m1.6 m626 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.8 m)(11.4 m)(11.2 m)(14.1 m)(16.2 m)(16.9 m)(15.7 m)(15.6 m)(14.2 m)(14.2 m)

Depreciation and Amortization

164 k

Accounts Payable

1.1 m1.2 m525 k1.6 m1.4 m2.4 m3.2 m3.7 m4.1 m

Cash From Operating Activities

(10.6 m)
USDY, 2017

Revenue/Employee

25 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Dicerna Pharmaceuticals News and Updates

Report incorrect company information